Evidence map›Paper›PMID 38755141›Full record

ArticleNature communications2024

The nucleic acid binding protein SFPQ represses EBV lytic reactivation by promoting histone H1 expression.

Laura A Murray-Nerger, Clarisel Lozano, Eric M Burton, Yifei Liao, Nathan A Ungerleider, Rui Guo, Benjamin E Gewurz

Abstract read
In one paragraph

Article in Nature communications, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed.

  1. Targeting the non-coding RNA-PANoptosis axis: a novel frontier in disease diagnosis and therapy.Apoptosis : an international journal on programmed cell death · 2026
    Review
  2. Reconstructing EBV reactivation and DNA damage response kinetics in morphologic pseudotime.Proceedings of the National Academy of Sciences of the United States of America · 2026
    Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Epstein-Barr Virus Encoded lncRNAs Control the Viral Lytic Switch.bioRxiv : the preprint server for biology · 2025
    Article
  10. Article
  11. Chromatin Control of EBV Infection and Latency.Current topics in microbiology and immunology · 2025
    Article
  12. Review
  13. Article
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Laura A Murray-NergerDivision of Infectious Diseases, Department of Medicine, Brigham and Women's Hospital, 181 Longwood Avenue, Boston, MA, 02115, USA.
Clarisel LozanoDivision of Infectious Diseases, Department of Medicine, Brigham and Women's Hospital, 181 Longwood Avenue, Boston, MA, 02115, USA.
Eric M BurtonDivision of Infectious Diseases, Department of Medicine, Brigham and Women's Hospital, 181 Longwood Avenue, Boston, MA, 02115, USA.
Yifei LiaoDivision of Infectious Diseases, Department of Medicine, Brigham and Women's Hospital, 181 Longwood Avenue, Boston, MA, 02115, USA.
Nathan A UngerleiderDepartment of Pathology, Tulane University, New Orleans, LA, 70118, USA.
Rui GuoDepartment of Molecular Biology and Microbiology, Tufts University, Medford, MA, 02155, USA.ORCID http://orcid.org/0000-0003-4584-1324
Benjamin E GewurzDivision of Infectious Diseases, Department of Medicine, Brigham and Women's Hospital, 181 Longwood Avenue, Boston, MA, 02115, USA. bgewurz@bwh.harvard.edu.ORCID http://orcid.org/0000-0002-3965-3418

Funding

Targeting the Epigenetic and Metabolic Control of EBV-Epithelial CancersP01CA269043 · NCI · WISTAR INSTITUTE · PI PAUL M. LIEBERMAN · 2023 to 2026
$12.0M
MOLECULAR BASIS OF VIRAL INFECTIVITYT32AI007245 · NIAID · HARVARD UNIVERSITY (MEDICAL SCHOOL) · PI Aaron Gregory Schmidt · 1985 to 2026
$11.3M
B cell determinants of EBV latency (supplement)U01CA275301 · NCI · WEILL MEDICAL COLL OF CORNELL UNIV · PI Ethel Cesarman, Benjamin Elison Gewurz · 2022 to 2026
$4.0M
Epstein-Barr virus LMP1 mediated oncogenicityR01CA228700 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI Benjamin Elison Gewurz · 2019 to 2026
$3.3M
Regulation of the Epstein-Barr Virus Lytic SwitchR01AI164709 · NIAID · BRIGHAM AND WOMEN'S HOSPITAL · PI Benjamin Elison Gewurz · 2021 to 2026
$3.1M
EBV reactivation causes widespread host de novo promoter transcription and transcriptional interferenceR01CA272142 · NCI · WAYNE STATE UNIVERSITY · PI ERIK K FLEMINGTON · 2022 to 2026
$2.1M
Exploiting Metabolism to Uncloak Epstein-Barr Virus Immunogens in Latently Infected B-cellsR00DE031016 · NIDCR · TUFTS UNIVERSITY BOSTON · PI GUO, RUI · 2023 to 2025
$747k
Characterization of Epstein-Barr Virus Subversion of the Host SMC5/6 Restriction PathwayR21AI170751 · NIAID · BRIGHAM AND WOMEN'S HOSPITAL · PI GEWURZ, BENJAMIN ELISON · 2023 to 2024
$492k
Exploiting Metabolism to Uncloak Epstein-Barr Virus Immunogens in Latently Infected B-cellsK99DE031016 · NIDCR · BRIGHAM AND WOMEN'S HOSPITAL · PI GUO, RUI · 2022 to 2023
$232k
Defining how the DNA- and RNA-binding protein SFPQ represses Epstein-Barr Virus lytic reactivationF32AI172329 · NIAID · BRIGHAM AND WOMEN'S HOSPITAL · PI MURRAY-NERGER, LAURA · 2022 to 2024
$147k
Foundation for the National Institutes of Health (Foundation for the National Institutes of Health, Inc.) AI007245Foundation for the National Institutes of Health (Foundation for the National Institutes of Health, Inc.) AI164709Foundation for the National Institutes of Health (Foundation for the National Institutes of Health, Inc.) AI170751Foundation for the National Institutes of Health (Foundation for the National Institutes of Health, Inc.) AI172329Foundation for the National Institutes of Health (Foundation for the National Institutes of Health, Inc.) CA228700Foundation for the National Institutes of Health (Foundation for the National Institutes of Health, Inc.) DE031016NCI NIH HHS P01 CA269043NCI NIH HHS R01 CA228700NCI NIH HHS R01 CA272142NCI NIH HHS U01 CA275301NIAID NIH HHS F32 AI172329NIAID NIH HHS R01 AI164709NIAID NIH HHS R21 AI170751NIAID NIH HHS T32 AI007245NIDCR NIH HHS K99 DE031016NIDCR NIH HHS R00 DE031016
6 · The paper itself

Abstract

Epstein-Barr virus (EBV) uses a biphasic lifecycle of latency and lytic reactivation to infect >95% of adults worldwide. Despite its central role in EBV persistence and oncogenesis, much remains unknown about how EBV latency is maintained. We used a human genome-wide CRISPR/Cas9 screen to identify that the nuclear protein SFPQ was critical for latency. SFPQ supported expression of linker histone H1, which stabilizes nucleosomes and regulates nuclear architecture, but has not been previously implicated in EBV gene regulation. H1 occupied latent EBV genomes, including the immediate early gene BZLF1 promoter. Upon reactivation, SFPQ was sequestered into sub-nuclear puncta, and EBV genomic H1 occupancy diminished. Enforced H1 expression blocked EBV reactivation upon SFPQ knockout, confirming it as necessary downstream of SFPQ. SFPQ knockout triggered reactivation of EBV in B and epithelial cells, as well as of Kaposi's sarcoma-associated herpesvirus in B cells, suggesting a conserved gamma-herpesvirus role. These findings highlight SFPQ as a major regulator of H1 expression and EBV latency.

Indexed as

Herpesvirus 4, HumanHistonesPTB-Associated Splicing FactorVirus ActivationVirus LatencyB-LymphocytesCRISPR-Cas SystemsEpstein-Barr Virus InfectionsGene Expression Regulation, ViralGenome, ViralHumansPromoter Regions, GeneticTrans-ActivatorsBZLF1 protein, Herpesvirus 4, HumanHistonesPTB-Associated Splicing FactorTrans-Activators

Identifiers

PMID38755141
PMCPMC11099029

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.